all'italiana 29 | 25 °C 27 | 24 °C 26 | 24 °C 27 | 24 °C 27 | 25 °C 27 | 25 °C 27 | 25 °C 42 | 18 °C 37 | 20 °C 33 | 18 °C 33 | 17 °C 33 | 17 °C 33 | 17 °C 34 | 18 °C 36| 19 °C 35 | 22 °C 35 | 23 °C 34 | 23 °C 33 | 23 °C 33 | 23 °C 34 | 24 °C 28 | 16 °C 25 | 19 °C 24 | 17 °C 24 | 17 °C 24 | 18°C 24 | 18°C 24 | 18°C 46 | 21 °C 29 | 24 °C 26| 23 °C 26| 22 °C 26 | 22 °C 26 | 22 °C 28 | 23 °C 27 | 16 °C 28 | 16 °C 31 | 18 °C 31 | 19 °C 31 | 19 °C 31 | 19 °C 31 | 19 °C 29 | 18 °C 26 | 18 °C 23 | 17 °C 23 | 17 °C 23 | 17 °C 23 | 17 °C 24 | 18 °C 26 | 16 °C 22 | 16 °C 21 | 13 °C 21 | 13 °C 22 | 13 °C 23 | 11 °C 22 | 10 °C dal 27 Gennaio al 2 Febbraio 2026 27 Gennaio 28 Gennaio 29 Gennaio 30 Gennaio 31 Gennaio 1 Febbraio 2 Febbraio Over the past decade, Italy has quietly become one of Europe’s most important pharmaceuti cal hubs. Production, research, jobs and exports have all surged, turning the sector into one of the strongest engines of the Italian economy. Today pharmaceuti cals account for about 10 per cent of Italy’s total exports, a re markable figure for an industry once seen as secondary to fash ion, food or machinery.
At the heart of this success are three pillars: multinational groups operating in Italy, a strong network of contract manufactur ers, and a core of Italian-owned companies known as the FAB13 – the 13 historic pharmaceutical firms of Made in Italy.
Together, they show how tradition and innovation can grow side by side. The FAB13 in clude well-known names such as Menarini, Chiesi, Recordati, Angelini, Zambon and Dompé.
According to a report by econo mist Marco Fortis of the Edison Foundation, their performance in 2024 was particularly strong.
Aggregate revenues rose by 12 per cent compared to 2023, reaching €18.9 billion. Foreign markets Italy’s Pharmaceutical Champions Power a New Made in Italy drove most of this growth, with international revenues up 14 per cent, while the domestic market grew only 2 per cent due to weak national demand.
Exports were the real star. The FAB13 recorded export growth of 16 per cent in 2024, far above the already impressive 10 per cent increase of Italy’s overall phar maceutical exports. Investments also surged: total investment (excluding acquisitions) grew by 21 per cent, while spending on re search and development jumped by 27 per cent to €1.4 billion.
Employment followed the same positive trend. The FAB13 workforce grew by 3 per cent overall, with a 2 per cent rise in Italy and 4 per cent abroad. In total t
Be the first to comment